Related Experiment Video
Updated: Aug 7, 2026
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Therapeutic apheresis in the Republic of Macedonia - our five years experience (2000-2004)
M Milovanceva-Popovska1, Lj Stojkovski, L Grcevska
1Department of Nephrology, Medical Faculty, Ss. Cyril and Methodius University, Skopje, R. Macedonia. majamil@freemail.com.mk
Abstract:
Membrane plasma exchange (PE) is a mode of extracorporeal blood purification. Since 1985 membrane PE has been in regular use at the Department of Nephrology, Medical Faculty of Skopje, R.Macedonia. In this paper we report on five years (2000-2004) of single centre plasma exchange activity. We performed 540 PE treatments (108 PE/per year) on 99 patients. The M/F ratio was 40/48. The patients underwent a median of 5.45 procedures (range, 1-16). The treated patients were from different Departments. Protocols for PE depend on the disease and its severity. PE were performed 2-4 times weekly using Gambro PF 2000 N filters with an adaptation of the Gambro AK10 dialysis machine or with the Gambro Prizma machine (2 cases). Blood access was achieved through femoral vein. Substitution was made with fresh frozen plasma and/or with 20% human albumin combined with Ringer's solution. An average amount of 2150 ml plasmafiltrate per treatment (respectively 30 to 40 ml plasmafiltrate/kg body weight) was eliminated. Most therapeutic procedures were performed on patients from the Department of Neurology. 63.6% of all patients were referred for Myasthenia gravis and the Guillian Barre syndrome. The total number of procedures per year has remained fairly stable, corresponding to a median of 5.4 treatments/100 000 inhabitants. We observed hypocalcaemia in 8% of the patients, urticarial reactions in 7.3%, pruritic reactions in 12%, and hypotension/headache in 6.8%. No major procedural complications were seen.
Insights
Membrane plasma exchange (PE) is an extracorporeal blood purification method. This study reports on five years of PE activity, showing its efficacy and safety in treating neurological disorders like Myasthenia gravis.
Area of Science:
- Nephrology
- Neurology
- Extracorporeal Therapies
Background:
- Membrane plasma exchange (PE) is a vital extracorporeal blood purification technique.
- Established in 1985, membrane PE has been consistently utilized at the Department of Nephrology, Medical Faculty of Skopje.
- This report details five years of single-center plasma exchange activity from 2000-2004.
Purpose of the Study:
- To analyze the single-center plasma exchange activity over a five-year period.
- To evaluate the application of PE in various patient populations, particularly those with neurological conditions.
- To assess the safety and complication profile of membrane PE procedures.
Main Methods:
- Conducted 540 PE treatments on 99 patients between 2000 and 2004.
- Utilized Gambro PF 2000 N filters with Gambro AK10 or Prizma machines.
- Administered substitution therapy with fresh frozen plasma, 20% human albumin, and Ringer's solution, removing an average of 2150 ml plasmafiltrate per treatment.
Main Results:
- The majority of procedures (63.6%) were for Myasthenia gravis and Guillain-Barré syndrome patients.
- An average of 108 PE treatments were performed annually, with a median of 5.4 treatments per 100,000 inhabitants.
- Observed adverse events included hypocalcemia (8%), urticarial reactions (7.3%), pruritic reactions (12%), and hypotension/headache (6.8%), with no major procedural complications.
Conclusions:
- Membrane plasma exchange is a stable and effective treatment modality, particularly for neurological diseases.
- The procedure demonstrates a favorable safety profile with manageable side effects.
- Continued application of PE is warranted for specific patient cohorts requiring extracorporeal blood purification.
